{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:00:02Z","timestamp":1781949602316,"version":"3.54.5"},"reference-count":77,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The efficiency of blood flowing from the heart depends on its electrical properties. Myocardial\nelectrical activity is associated with generating cardiac action potentials in isolated myocardial\ncells and their coordinated propagation, which are mediated by gap junctions. Atrial fibrillation\n(AF) is a common cardiac arrhythmia which causes an aggressive disturbance in cardiac\nelectromechanical function. Moreover, AF increases the risk of stroke and mortality and is a major\ncause of death. The mechanisms underlying AF involve electrophysiological changes in ion channel\nexpression and function. \u03b2-blockers may be useful in patients with chronic AF or in preventing\npostoperative AF in subjects undergoing coronary artery bypass grafting (CABG) or other types of\nsurgery. The reduction in heart rate induced by \u03b21-adrenergic receptor antagonists may be associated\nwith the beneficial effect of this drug class. Second generation beta-blockers may be considered\nsuperior to the first generation due to their selectivity to the \u03b21 receptor as well as avoiding\npulmonary or metabolic adverse effects. Third generation beta-blockers may be considered a great\noption for their vasodilation and antioxidant properties. There is also a new \u03b2-blocker, named\nlandilol that also results on reduced risk of post operative AF without adverse effects and its use\nhas been increasing in clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573402118666220609161044","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T06:13:39Z","timestamp":1655100819000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Three Generation \u03b2-Blockers for Atrial Fibrillation Treatment"],"prefix":"10.2174","volume":"19","author":[{"given":"Arthur C.","family":"Francisco","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University Center of Barra Mansa, Barra Mansa-RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanessa M. C.","family":"Awata","sequence":"additional","affiliation":[{"name":"Department of\nPharmacology, Ribeirao Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto-SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thauann S.","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Dentistry,\nUniversity Center of Volta Redonda - UniFOA, Volta Redonda-RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone R.","family":"Potje","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University,\nIndianapolis-IN, USA"},{"name":"Department of Biomedical and Health Sciences, Minas Gerais State University, Passos-MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare C.","family":"Prohaska","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University,\nIndianapolis-IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S.","family":"Ceron","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Federal University of Ouro Preto, Ouro Preto-\nMG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T. do","family":"Vale","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Health Sciences, Minas Gerais State University, Passos-MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Sundjaja J.H.","year":"2021","unstructured":"Sundjaja J.H.; Bordoni B.;  Anatomy, Thorax, Heart Pulmonic Valve 2021","journal-title":"Anatomy, Thorax, Heart Pulmonic Valve"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1054-8807(01)00078-3","volume":"10","author":"Kanno S.","year":"2001","unstructured":"Kanno S.; Saffitz J.E.; The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 2001,10(4),169-177","journal-title":"Cardiovasc Pathol"},{"key":"ref=3","first-page":"654","volume":"2","author":"Antzelevitch C.","year":"2002","unstructured":"Antzelevitch C.; Dumaine R.; Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications. Handbook of Physiology. The Cardiovascular System. Heart 2002,2(1),654-692","journal-title":"Heart"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1152\/physrev.00007.2003","volume":"83","author":"Saez J.C.","year":"2003","unstructured":"Saez J.C.; Berthoud V.M.; Branes M.C.; Martinez A.D.; Beyer E.C.; Plasma membrane channels formed by connexins: Their regulation and functions. Physiol Rev 2003,83(4),1359-1400","journal-title":"Physiol Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.tcm.2003.12.006","volume":"14","author":"Nerbonne J.M.","year":"2004","unstructured":"Nerbonne J.M.; Studying cardiac arrhythmias in the mouse-a reasonable model for probing mechanisms? Trends Cardiovasc Med 2004,14(3),83-93","journal-title":"Trends Cardiovasc Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1152\/physrev.00002.2005","volume":"85","author":"Nerbonne J.M.","year":"2005","unstructured":"Nerbonne J.M.; Kass R.S.; Molecular physiology of cardiac repolarization. Physiol Rev 2005,85(4),1205-1253","journal-title":"Physiol Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1046\/j.1540-8167.2002.00406.x","volume":"13","author":"Nerbonne J.M.","year":"2002","unstructured":"Nerbonne J.M.; Guo W.; Heterogeneous expression of voltage-gated potassium channels in the heart: Roles in normal excitation and arrhythmias. J Cardiovasc Electrophysiol 2002,13(4),406-409","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1046\/j.1540-8167.2003.03316.x","volume":"14","author":"Antzelevitch C.","year":"2003","unstructured":"Antzelevitch C.; Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. J Cardiovasc Electrophysiol 2003,14(11),1259-1272","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1152\/physrev.00025.2003","volume":"84","author":"Kl\u00e9ber A.G.","year":"2004","unstructured":"Kl\u00e9ber A.G.; Rudy Y.; Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004,84(2),431-488","journal-title":"Physiol Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1540-8167.1992.tb00990.x","volume":"3","author":"Delmar M.","year":"1992","unstructured":"Delmar M.; Role of potassium currents on cell excitability in cardiac ventricular myocytes. J Cardiovasc Electrophysiol 1992,3(5),474-486","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1172\/JCI0215928","volume":"110","author":"Clancy C.E.","year":"2002","unstructured":"Clancy C.E.; Tateyama M.; Kass R.S.; Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. J Clin Invest 2002,110(9),1251-1262","journal-title":"J Clin Invest"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1161\/01.RES.74.6.1071","volume":"74","author":"Luo C.H.","year":"1994","unstructured":"Luo C.H.; Rudy Y.; A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res 1994,74(6),1071-1096","journal-title":"Circ Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/01.RES.74.6.1097","volume":"74","author":"Luo C.H.","year":"1994","unstructured":"Luo C.H.; Rudy Y.; A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ Res 1994,74(6),1097-1113","journal-title":"Circ Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-4684-6015-5_11","volume":"308","author":"Fozzard H.A.","year":"1991","unstructured":"Fozzard H.A.; Excitation-contraction coupling in the heart. Adv Exp Med Biol 1991,308,135-142","journal-title":"Adv Exp Med Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0008-6363(02)00407-8","volume":"55","author":"Fozzard H.A.","year":"2002","unstructured":"Fozzard H.A.; Cardiac sodium and calcium channels: A history of excitatory currents. Cardiovasc Res 2002,55(1),1-8","journal-title":"Cardiovasc Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1146\/annurev.ph.41.030179.002353","volume":"41","author":"Fabiato A.","year":"1979","unstructured":"Fabiato A.; Fabiato F.; Calcium and cardiac excitation-contraction coupling. Annu Rev Physiol 1979,41(1),473-484","journal-title":"Annu Rev Physiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0008-6363(99)00038-3","volume":"42","author":"Bers D.M.","year":"1999","unstructured":"Bers D.M.; Perez-Reyes E.; Ca channels in cardiac myocytes: Structure and function in Ca influx and intracellular Ca release. Cardiovasc Res 1999,42(2),339-360","journal-title":"Cardiovasc Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccl.2008.09.015","volume":"27","author":"Kannel W.B.","year":"2009","unstructured":"Kannel W.B.; Benjamin E.J.; Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009,27(1),13-24","journal-title":"Cardiol Clin"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC201703070","volume":"166","author":"Zimetbaum P.","year":"2017","unstructured":"Zimetbaum P.; Atrial fibrillation. Ann Intern Med 2017,166(5),ITC33-ITC48","journal-title":"Ann Intern Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11883-017-0638-1","volume":"19","author":"Pi\u00f1a P.G.","year":"2017","unstructured":"Pi\u00f1a P.G.; Chicos A.B.; Early cardioversion in atrial fibrillation: Earlier is better, but not always and (maybe) not immediately. Curr Atheroscler Rep 2017,19(1),3","journal-title":"Curr Atheroscler Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/01.CIR.89.1.224","volume":"89","author":"Page R.L.","year":"1994","unstructured":"Page R.L.; Wilkinson W.E.; Clair W.K.; McCarthy E.A.; Pritchett E.L.; Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994,89(1),224-227","journal-title":"Circulation"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.ahj.2006.08.011","volume":"152","author":"Reynolds M.R.","year":"2006","unstructured":"Reynolds M.R.; Lavelle T.; Essebag V.; Cohen D.J.; Zimetbaum P.; Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: The Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J 2006,152(6),1097-1103","journal-title":"Am Heart J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCULATIONAHA.109.925610","volume":"122","author":"Zimetbaum P.","year":"2010","unstructured":"Zimetbaum P.; Goldman A.; Ambulatory arrhythmia monitoring: Choosing the right device. Circulation 2010,122(16),1629-1636","journal-title":"Circulation"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","volume":"370","author":"Sanna T.","year":"2014","unstructured":"Sanna T.; Diener H.C.; Passman R.S.; Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014,370(26),2478-2486","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1124\/jpet.103.049270","volume":"305","author":"Goldstein D.S.","year":"2003","unstructured":"Goldstein D.S.; Eisenhofer G.; Kopin I.J.; Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003,305(3),800-811","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1113\/expphysiol.2008.045179","volume":"94","author":"Audigane L.","year":"2009","unstructured":"Audigane L.; Kerfant B.G.; El Harchi A.; Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors. Exp Physiol 2009,94(4),400-411","journal-title":"Exp Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.tcm.2012.06.017","volume":"22","author":"Galougahi K.K.","year":"2012","unstructured":"Galougahi K.K.; Liu C.C.; Bundgaard H.; Rasmussen H.H.; \u03b2-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. Trends Cardiovasc Med 2012,22(4),83-87","journal-title":"Trends Cardiovasc Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1573402114666180918102735","volume":"15","author":"do Vale G.T.","year":"2019","unstructured":"do Vale G.T.; Ceron C.S.; Gonzaga N.A.; Simplicio J.A.; Padovan J.C.; Three generations of \u03b2-blockers: History, class differences and clinical applicability. Curr Hypertens Rev 2019,15(1),22-31","journal-title":"Curr Hypertens Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/eci.12598","volume":"46","author":"Najafi A.","year":"2016","unstructured":"Najafi A.; Sequeira V.; Kuster D.W.D.; van der Velden J.; \u03b2-adrenergic receptor signalling and its functional consequences in the diseased heart. Eur J Clin Invest 2016,46(4),362-374","journal-title":"Eur J Clin Invest"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev.pharmtox.39.1.343","volume":"39","author":"Post S.R.","year":"1999","unstructured":"Post S.R.; Hammond H.K.; Insel P.A.; Beta-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol 1999,39(1),343-360","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/eurheartj\/10.suppl_B.29","volume":"10","author":"Kaumann A.J.","year":"1989","unstructured":"Kaumann A.J.; Hall J.A.; Murray K.J.; Wells F.C.; Brown M.J.; A comparison of the effects of adrenaline and noradrenaline on human heart: The role of \u03b2 1- and \u03b2 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 1989,10(Suppl. B),29-37","journal-title":"Eur Heart J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fneur.2014.00051","volume":"5","author":"Berg T.","year":"2014","unstructured":"Berg T.; Beta1-blockers lower norepinephrine release by inhibiting presynaptic, facilitating \u03b21-adrenoceptors in normotensive and hypertensive rats. Front Neurol 2014,5,51","journal-title":"Front Neurol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1152\/ajplegacy.1976.230.2.410","volume":"230","author":"Johnson J.A.","year":"1976","unstructured":"Johnson J.A.; Davis J.O.; Gotshall R.W.; Evidence for an intrarenal beta receptor in control of renin release. Am J Physiol 1976,230(2),410-418","journal-title":"Am J Physiol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.36660\/abc.20201238","volume":"116","author":"Barroso W.K.S.","year":"2021","unstructured":"Barroso W.K.S.; Rodrigues C.I.S.; Bortolotto L.A.; Brazilian guidelines of hypertension \u2013 2020. Arq Bras Cardiol 2021,116(3),516-558","journal-title":"Arq Bras Cardiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pcad.2004.04.004","volume":"47","author":"Reiter M.J.","year":"2004","unstructured":"Reiter M.J.; Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis 2004,47(1),11-33","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(64)91275-9","volume":"1","author":"Black J.W.","year":"1964","unstructured":"Black J.W.; Crowther A.F.; Shanks R.G.; Smith L.H.; Dornhorst A.C.; A new adrenergic betareceptor antagonist. Lancet 1964,1(7342),1080-1081","journal-title":"Lancet"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.0954-6820.1974.tb08159.x","volume":"195","author":"Hansson L.","year":"1974","unstructured":"Hansson L.; Zweifler A.J.; The effct of propranolol on plasma renin activity and blood pressure in mild essential hypertension. Acta Med Scand 1974,195(5),397-401","journal-title":"Acta Med Scand"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1440-1843.2000.00236.x","volume":"5","author":"Boskabady M.H.","year":"2000","unstructured":"Boskabady M.H.; Snashall P.D.; Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta-blockade in asthma. Respirology 2000,5(2),111-118","journal-title":"Respirology"},{"key":"ref=39","first-page":"53","volume":"33","author":"Marsden C.D.","year":"1967","unstructured":"Marsden C.D.; Foley T.H.; Owen D.A.; McAllister R.G.; Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci 1967,33(1),53-65","journal-title":"Clin Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0140-6736(79)90821-3","volume":"1","author":"Lager I.","year":"1979","unstructured":"Lager I.; Blohm\u00e9 G.; Smith U.; Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet 1979,1(8114),458-462","journal-title":"Lancet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1365-2125.1990.tb03689.x","volume":"29","author":"Kerr D.","year":"1990","unstructured":"Kerr D.; MacDonald I.A.; Heller S.R.; Tattersall R.B.; Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990,29(6),685-693","journal-title":"Br J Clin Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM196508192730802","volume":"273","author":"Harrison D.C.","year":"1965","unstructured":"Harrison D.C.; Griffin J.R.; Fiene T.J.; Effects of beta-adrenergic blockade with propranolol in patients with atrial arrhythmias. N Engl J Med 1965,273(8),410-415","journal-title":"N Engl J Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1755-5922.2009.00100.x","volume":"27","author":"Kojuri J.","year":"2009","unstructured":"Kojuri J.; Mahmoodi Y.; Jannati M.; Shafa M.; Ghazinoor M.; Sharifkazemi M.B.; Ability of amiodarone and propranolol alone or in combination to prevent post-coronary bypass atrial fibrillation. Cardiovasc Ther 2009,27(4),253-258","journal-title":"Cardiovasc Ther"},{"key":"ref=44","volume":"9","author":"Blessberger H.","year":"2019","unstructured":"Blessberger H.; Lewis S.R.; Pritchard M.W.; Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery. Cochrane Database Syst Rev 2019,9","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1476-5381.1968.tb00444.x","volume":"32","author":"Dunlop D.","year":"1968","unstructured":"Dunlop D.; Shanks R.G.; Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother 1968,32(1),201-218","journal-title":"Br J Pharmacol Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/0002-9149(75)90050-8","volume":"35","author":"Pribble A.H.","year":"1975","unstructured":"Pribble A.H.; Conn R.D.; The use of practolol in supraventricular arrhythmias associated with acute illnesses. Am J Cardiol 1975,35(5),645-650","journal-title":"Am J Cardiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1378\/chest.71.5.592","volume":"71","author":"Yahalom J.","year":"1977","unstructured":"Yahalom J.; Klein H.O.; Kaplinsky E.; Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest 1977,71(5),592-596","journal-title":"Chest"},{"key":"ref=48","first-page":"340P","volume":"48","author":"Barrett A.M.","year":"1973","unstructured":"Barrett A.M.; Carter J.; Fitzgerald J.D.; Hull R.; Le Count D.; A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol 1973,48(2),340P","journal-title":"Br J Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005344-198901000-00002","volume":"13","author":"Lewis R.V.","year":"1989","unstructured":"Lewis R.V.; McMurray J.; McDevitt D.G.; Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989,13(1),1-6","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=50","first-page":"229","volume":"5","author":"Matangi M.F.","year":"1989","unstructured":"Matangi M.F.; Strickland J.; Garbe G.J.; Atenolol for the prevention of arrhythmias following coronary artery bypass grafting. Can J Cardiol 1989,5(4),229-234","journal-title":"Can J Cardiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0024-3205(73)90368-8","volume":"12","author":"Ablad B.","year":"1973","unstructured":"Ablad B.; Carlsson E.; Ek L.; Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. Life Sci I 1973,12(3),107-119","journal-title":"Life Sci I"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jelectrocard.2015.07.019","volume":"48","author":"Sandberg F.","year":"2015","unstructured":"Sandberg F.; Corino V.D.; Mainardi L.T.; Non-invasive assessment of the effect of beta blockers and calcium channel blockers on the AV node during permanent atrial fibrillation. J Electrocardiol 2015,48(5),861-866","journal-title":"J Electrocardiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1751-7133.2012.00309.x","volume":"19","author":"Silvet H.","year":"2013","unstructured":"Silvet H.; Hawkins L.A.; Jacobson A.K.; Heart rate control in patients with chronic atrial fibrillation and heart failure. Congest Heart Fail 2013,19(1),25-28","journal-title":"Congest Heart Fail"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1556\/1646.9.2017.11","volume":"9","author":"Kamali A.","year":"2017","unstructured":"Kamali A.; Sanatkar A.; Sharifi M.; Moshir E.; Evaluation of amiodarone versus metoprolol in treating atrial fibrillation after coronary artery bypass grafting. Interv Med Appl Sci 2017,9(2),51-55","journal-title":"Interv Med Appl Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3B","DOI":"10.1016\/j.amjcard.2004.01.003","volume":"93","author":"Dulin B.","year":"2004","unstructured":"Dulin B.; Abraham W.T.; Pharmacology of carvedilol. Am J Cardiol 2004,93(9A),3B-6B","journal-title":"Am J Cardiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11906-007-0050-2","volume":"9","author":"Pedersen M.E.","year":"2007","unstructured":"Pedersen M.E.; Cockcroft J.R.; The vasodilatory beta-blockers. Curr Hypertens Rep 2007,9(4),269-277","journal-title":"Curr Hypertens Rep"},{"key":"ref=57","first-page":"159","volume":"12","author":"De Cree J.","year":"1992","unstructured":"De Cree J.; Van Nueten L.; Geukens H.; Verhaegen H.; Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 1992,12(4),159-163","journal-title":"Int J Clin Pharmacol Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1476-5381.1972.tb08125.x","volume":"45","author":"Farmer J.B.","year":"1972","unstructured":"Farmer J.B.; Kennedy I.; Levy G.P.; Marshall R.J.; Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol 1972,45(4),660-675","journal-title":"Br J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/chir.20673","volume":"21","author":"Carvalho T.M.","year":"2009","unstructured":"Carvalho T.M.; Cavalli R.C.; Marques M.P.; Da Cunha S.P.; Baraldi C.O.; Lanchote V.L.; Stereoselective analysis of labetalol in human plasma by LC-MS\/MS: Application to pharmacokinetics. Chirality 2009,21(8),738-744","journal-title":"Chirality"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1476-5381.1990.tb14104.x","volume":"100","author":"Krumpl G.","year":"1990","unstructured":"Krumpl G.; Todt H.; Krejcy K.; Raberger G.; Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation. Br J Pharmacol 1990,100(4),855-861","journal-title":"Br J Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/0002-9149(90)91102-C","volume":"66","author":"Wong C.K.","year":"1990","unstructured":"Wong C.K.; Lau C.P.; Leung W.H.; Cheng C.H.; Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol 1990,66(17),1212-1215","journal-title":"Am J Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"53B","DOI":"10.1016\/j.amjcard.2004.01.023","volume":"93","author":"Gheorghiade M.","year":"2004","unstructured":"Gheorghiade M.; Lukas M.A.; Lukas M.A.; Role of carvedilol in atrial fibrillation: Insights from clinical trials. Am J Cardiol 2004,93(9A),53B-57B","journal-title":"Am J Cardiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4021\/jocmr1581w","volume":"5","author":"Kodani E.","year":"2013","unstructured":"Kodani E.; Matsumoto S.; Igawa O.; Kusama Y.; Atarashi H.; Effect of carvedilol on reduction in heart rate in patients with chronic atrial fibrillation. J Clin Med Res 2013,5(6),451-459","journal-title":"J Clin Med Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/0976-500X.142430","volume":"5","author":"Chitrapu R.V.","year":"2014","unstructured":"Chitrapu R.V.; Rao P.R.; Reddy G.V.; Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation. J Pharmacol Pharmacother 2014,5(4),239-244","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.hrthm.2007.04.022","volume":"4","author":"Haghjoo M.","year":"2007","unstructured":"Haghjoo M.; Saravi M.; Hashemi M.J.; Optimal \u03b2-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: Carvedilol versus metoprolol. Heart Rhythm 2007,4(9),1170-1174","journal-title":"Heart Rhythm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/00005344-198805000-00007","volume":"11","author":"Van de Water A.","year":"1988","unstructured":"Van de Water A.; Janssens W.; Van Neuten J.; Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988,11(5),552-563","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2125.1994.tb04342.x","volume":"38","author":"Bowman A.J.","year":"1994","unstructured":"Bowman A.J.; Chen C.P.; Ford G.A.; Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994,38(3),199-204","journal-title":"Br J Clin Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.coph.2012.12.002","volume":"13","author":"Vanhoutte P.M.","year":"2013","unstructured":"Vanhoutte P.M.; Gao Y.; Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013,13(2),265-273","journal-title":"Curr Opin Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.cjca.2014.03.003","volume":"30","author":"Howlett J.G.","year":"2014","unstructured":"Howlett J.G.; Howlett M.D.; Nebivolol: Vasodilator properties and evidence for relevance in treatment of cardiovascular disease. Can J Cardiol 2014,30(5)(Suppl.),S29-S37","journal-title":"Can J Cardiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s40265-018-0999-y","volume":"78","author":"Cicero A.F.G.","year":"2018","unstructured":"Cicero A.F.G.; Kuwabara M.; Borghi C.; A critical review of nebivolol and its fixed-dose combinations in the treatment of hypertension. Drugs 2018,78(17),1783-1790","journal-title":"Drugs"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bcpt.13248","volume":"125","author":"Olawi N.","year":"2019","unstructured":"Olawi N.; Kr\u00fcger M.; Grimm D.; Infanger M.; Wehland M.; Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol 2019,125(3),189-201","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=72","first-page":"52","volume":"43","author":"Shubik IuV.","year":"2003","unstructured":"Shubik IuV.; Medvedev M.M.; Kriatova T.V.; Heart rate control with nebivolol in patients with tachysystolic atrial fibrillation. Kardiologiia 2003,43(9),52-55","journal-title":"Kardiologiia"},{"key":"ref=73","first-page":"38","volume":"79","author":"Tepliakov A.T.","year":"2007","unstructured":"Tepliakov A.T.; Kuznetsova A.V.; Lukinov A.V.; Levshin A.V.; Effects of a superselective beta1-adrenoblocker nebivolol on the course of coronary heart disease and insulin resistance in patients with diabetes mellitus type 2 after coronary artery bypass grafting. Ter Arkh 2007,79(12),38-43","journal-title":"Ter Arkh"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"581","DOI":"10.5935\/1678-9741.20140078","volume":"29","author":"Erdil N.","year":"2014","unstructured":"Erdil N.; Kaynak M.; D\u00f6nmez K.; Disli O.M.; Battaloglu B.; Nebivolol in preventing atrial fibrillation following coronary surgery in patients over 60 years of age. Rev Bras Cir Cardiovasc 2014,29(4),581-587","journal-title":"Rev Bras Cir Cardiovasc"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1365-2710.2011.01315.x","volume":"37","author":"Nakano T.","year":"2012","unstructured":"Nakano T.; Shimizu K.; Kawashima O.; Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. J Clin Pharm Ther 2012,37(4),431-435","journal-title":"J Clin Pharm Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jtcvs.2010.10.045","volume":"141","author":"Sezai A.","year":"2011","unstructured":"Sezai A.; Minami K.; Nakai T.; Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial. J Thorac Cardiovasc Surg 2011,141(6),1478-1487","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1093\/eurheartj\/sux036","volume":"20","author":"Balik M.","year":"2018","unstructured":"Balik M.; Sander M.; Trimmel H.; Heinz G.; Landiolol for managing post-operative atrial fibrillation. Eur Heart J Suppl 2018,20(Suppl. A),A10-A14","journal-title":"Eur Heart J Suppl"}],"container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573402118666220609161044","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205807\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573402118666220609161044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T17:54:06Z","timestamp":1692554046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205807\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402118666220609161044","relation":{},"ISSN":["1573-4021"],"issn-type":[{"value":"1573-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}